From GlobeNewswire:

Ultragenyx Pharmaceutical Inc. has granted 13,020 restricted stock units to eight newly hired non-executive officers. The stock units will vest over four years, with 25% vesting on each anniversary of the grant date, contingent on continuous employment. Ultragenyx focuses on developing therapies for rare and ultrarare genetic diseases, with a management team experienced in rare disease therapeutics. The company aims for efficient drug development to deliver safe and effective treatments with urgency to patients in need. For more information, visit Ultragenyx’s website. If seeking more information, contact Joshua Higa at (415) 475-6370.



Read more at GlobeNewswire: Ultragenyx Reports Inducement Grant Under Nasdaq Listing